Olga Garcia Garcia

Olga Garcia Garcia


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2017 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
OGOlga Garcia Garcia
Olga Garcia Garcia
SJSara Jordan-Cumplido
Sara Jordan-Cumplido
OSOlaia Subira-Gonzalez
Olaia Subira-Gonzalez
PGPere Garcia-Bru
Pere Garcia-Bru
LALuis Arias
Luis Arias
JCJosep M. Caminal-Mitjana
Josep M. Caminal-Mitjana

7 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LVLaura Vigués-Jorba
Laura Vigués-Jorba
DLDaniel Lorenzo
Daniel Lorenzo
CPCristina Pujadas
Cristina Pujadas
RMRahul Morwani
Rahul Morwani
LYLiria Yamamoto-Rodriguez
Liria Yamamoto-Rodriguez
JCJosep Caminal
Josep Caminal
In this study, we aimed to identify the features of indeterminate choroidal melanocytic lesions visualized on optical coherence tomography angiography (OCTA) and to identify the predictors of growth. We retrospectively evaluated 86 patients with indeterminate lesions treated at our centre from 2016 to 2021. Clinical management involved active surveillance followed by brachytherapy if growth was detected. The lesions were classified into two groups according to whether they grew (small melanomas) or remained stable (choroidal nevi). Growth was detected in 19 (22.1%) lesions. All patients underwent OCTA at baseline. These images were compared to identify the possible predictors of growth. Significant between-group differences were observed in thickness (p = 0.00), greatest basal diameter (p = 0.00), number of risk factors (p = 0.00), symptoms (p = 0.001; relative risk [RR]: 4.3), orange pigment (p = 0.00; RR: 6.02), and ultrasonographic hollowness (Kappa sign); p = 0.000; RR: 5.3). The melanomas had significantly more vessels with a diameter ≥ 76.3 µm (p = 0.02; RR: 2.46). The time to growth in these lesions was significantly shorter (p = 0.05) than in lesions with smaller vessels. These findings show that vessel diameter quantified by OCTA can help differentiate between choroidal nevi and small melanomas, when considered together with clinical risk factors.

3 December 2015 in Blood
Verified
Journal Article
Open access
SASara Alonso
Sara Alonso
MAMiguel Alcoceba
Miguel Alcoceba
LMLaura Magnano
Laura Magnano
MAMarcio Andrade
Marcio Andrade
MGMaría García-Álvarez
María García-Álvarez
MCMaria Dolores Caballero
Maria Dolores Caballero
INTRODUCTION Follicular lymphoma (FL) may, over time, transform into an aggressive lymphoma, usually diffuse large B-cell lymphoma (DLBCL). Transformed follicular lymphomas (tFL) have a worse prognosis due to poorer response to treatment than primary DLBCL. The incidence of transformation is estimated in ~3% per year, although it varies largely between different studies (24%-70% overall). These differences are mainly due to different criteria to define tFL, to lack of evidence of tFL by biopsy, absence of clonality studies discarding secondary de novo NHL, studies performed in the pre-Rituximab era, or different follow-up times among studies. With all this pitfalls, the actual incidence of transformation remains an open question. The aim of the present study is to analyse the incidence and prognostic impact of transformation in patients with FL in a large retrospective series of the Spanish group of Lymphomas (GELTAMO). PATIENTS&METHODS A total of 1763 patients from 19 Spanish centres diagnosed of FL between 2000 and 2011 were recruited in the study. Data were obtained from the database of centres willing to participate in this study. True tFL (FL to DLBCL) were recorded. From the original cohort, FL IIIb, composite FL+DLBCL, discordant FL (FL in bone marrow and DLBCL in adenopathy or viceversa), and downgrading tFL (DLBCL at diagnosis and relapse of FL) were excluded. Patients with inadequate follow-up were not considered. Therefore, 1611 patients (grade I, II, and IIIa) were finally included. This study was approved by the Salamanca University Hospital Ethic Committee. RESULTS One hundred and ten patients (median follow up of 6 years) were transformed to DLBCL. Cumulative incidence of transformation at 5, 10, and 15 years was of 5%, 9%, and 14%, respectively. With a median follow up of 75.9 months (2 to 179), median time to transformation was 66 months, ranged 1-179. Considering survival from diagnosis of FL, tFL patients had a shorter OS than non-transformed (19% vs. 69%, p<0,0001). Most of the tFL patients (92%) have previously received treatment for FL, 63% of them with Rituximab. Median number of treatment lines before transformation was 2 (1-7). Factors influencing risk of tFL in the multivariate analysis included non-response to first line therapy (PR, p<0.001, HR:2,5 95% CI:1.5-4.2; others, p2 (p=0.002, HR: 2,1 95% CI: 1.3-3.4). In the multivariate analysis, factors predicting decreased OS after transformation included non-achievement of CR after first line therapy (p<0,001, HR:4.3 95% CI:2-9.1), and elevated LDH at the moment of transformation (p=0,003, HR:3 95% CI:1.5-6.3). We analyzed separately the role of autologous stem cell transplantation (ASCT) in transformed FL patients. Patients that received ASCT were significantly younger (<70 years) p<0,001, had a better performance status (ECOG <2) (p=0,008) and had achieved a better response (CR) (p=2) and non-response to FL first line therapy were associated with a higher risk of transformation.Only non-response to transformed FL treatment therapy and a high LDH at transformation were associated with a worse OS after transformation in the multivariate analysis. Autologous transplantation in transformed patients could have a benefit in terms of OS after transformation, but after the introduction of immunochemotherapy strategies, perhaps patients responding to treatment after transformation do not beneficiate from this strategy. *Equal contribution; ‡Equal senior contribution

4 December 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
Alexander Anduaga-BeramendiAlexander Anduaga-Beramendi
Alexander Anduaga-Beramendi
MCMarta Caminal-Caramés
Marta Caminal-Caramés
DLDaniel Lorenzo
Daniel Lorenzo
ECEstefania Cobos
Estefania Cobos
MMMilagros Mateos-Olivares
Milagros Mateos-Olivares
JCJosep Caminal
Josep Caminal
To assess the outcomes of a modified surgical approach for the treatment of uveal melanoma involving endoresection with intentional residual tumor at the margins, combined with adjuvant ruthenium-106 brachytherapy. This technique aims to reduce surgical morbidity, while preserving visual function and maintaining effective local tumor control and survival. We conducted a retrospective observational study including 33 patients with choroidal melanoma treated between January 2017 and August 2024 at a single tertiary ocular oncology center in Spain. Patients underwent pars plana vitrectomy and endoresection leaving residual tumor followed by ruthenium-106 brachytherapy. Clinical, functional, and oncological outcomes were analyzed, including tumor recurrence, metastasis, visual acuity, complications, and cytogenetic findings. Kaplan–Meier analysis was used to estimate survival and recurrence rates. After a mean follow-up of 41.7 months, local tumor recurrence occurred in 2 patients (6.06%) and enucleation was performed in 1 patient (3.03%). Two patients (6.06%) developed metastases, with one disease-specific death, resulting in a 5-year survival rate of 97%. Visual acuity of 20/200 or better was preserved in 60.61% of patients. The most frequent complications were retinal detachment (36.36%) and macular edema (45.45%). Cytogenetic analysis showed a significant association between chromosome 1p loss and both recurrence and metastasis (p = 0.032). No cases of phthisis bulbi or severe hypotony were observed. This modified endoresection technique with intentional tumor residuals and adjuvant ruthenium-106 brachytherapy offers a safe and function-preserving option for selected patients with choroidal melanoma. It achieves good tumor control and visual outcomes, with a low rate of enucleation and metastasis. Further studies are required to validate its long-term efficacy.

5 February 2026 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
OGOlga Garcia Garcia
Olga Garcia Garcia
JMJoaquim Marcoval
Joaquim Marcoval
AIAdriana Iriarte
Adriana Iriarte
GRGemma Rocamora
Gemma Rocamora
JMJuan Mañá
Juan Mañá
Sarcoidosis is a multisystem granulomatous disease that predominantly involves mediastinal lymph nodes and lungs but can also cause lesions in multiple organs. Ocular sarcoidosis (OS) has been repo...

1 May 2013 in Medicina Clinica
Verified
Journal Article
Closed access
RIRoger Argelich Ibáñez
Roger Argelich Ibáñez
JMJosep Maria Caminal Mitjana
Josep Maria Caminal Mitjana
PGPere Garcia-Bru
Pere Garcia-Bru
LALluís Arias-Barquet
Lluís Arias-Barquet
OGOlga Garcia Garcia
Olga Garcia Garcia
NSNatàlia Juan Serra
Natàlia Juan Serra